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Abstract
The chance of an intrathyroidal occurrence of a parathyroid gland is about 1–3%. Among the causes
of hyperparathyroidism, parathyroid cases occur in less than 1% of patients. Here we present the
case of a 63 year old Saudi female suffering from an intrathryroidal parathyroid carcinoma. The
suspicion coming from the clinical investigations that the removed tumor tissue may be a
parathyroid carcinoma could be confirmed by histology. Additionally non-radioactive in situ
hybridization to localize mRNA transcripts for Cyclin D1 and immunohistochemical localization of
Cyclin D1 was performed. Although parathyroid adenoma and carcinoma have disparate natural
history, it can be difficult to differentiate between the two entities. Clinical presentation, operative
findings may raise suspicion, but may not be conclusive especially if there is no evidence of invasion
or metastasis, especially if the gland was intrathyroidal.
Background
Parathyroid adenomas account for 85% of primary hyper-
parathyroidism [1]. On the other hand, parathyroid carci-
noma is a rare disease that accounts only for 1% to 3% of
cases of primary hyperparathyroidism [2,3] and to the
best of our knowledge, intrathyroidal parathyroid carci-
noma have been reported only three times [3]. The diag-
nosis and appropriate treatment of intrathyroidal
parathyroid carcinoma is difficult and its treatment is
more challenging to the surgeons. Adenomas and carcino-
mas of the parathyroid gland have disparate natural histo-
ries, but it can be difficult to differentiate them on the
basis of clinical and histological findings alone. Thick
fibrous bands, mitotic activity, trabecular growth pattern
and capsular, vascular, and adjacent soft tissue invasion
have been considered characteristic of parathyroid carci-
noma, but some of these morphological features (fibrous
bands, mitotic activity, trabecular growth) have been
identified in parathyroid adenomas as well [4]. Clarifica-
tion of the molecular pathogenesis of parathyroid carci-
noma can aid in diagnostically difficult cases and may
provide important clues for a more effective therapy. Cyc-
lin D1 (CD1) or PRAD1 is a protoncogene located at chro-
mosome band 11q13 and its protein product is a cell cycle
regulator [5]. Cyclin D1 gene amplification has been
implicated in the pathogenesis of numerous tumors [5-7].
Recently, Hsi et al. [6] demonstrated the over expression
of the cyclin D1 oncogene in 18% of 65 patients with par-
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athyroid tumors. They think that over expressed cyclin D1
plays a role in the pathogenesis of a much larger propor-
tion of parathyroid adenomas than previously assumed.
Cyclin D1 overexpression is a feature of typical parathy-
roid adenomas as had been suggested by early DNA stud-
ies [7]. Although His et al studied only three patients with
parathyroid carcinoma, two of the patients tumors stained
strongly for Cyclin D1, raising the possibility that the fre-
quency of Cyclin D1 overexpression may be greater in car-
cinoma. Cyclin D1 overexpression appears to highlight a
central pathway in parathyroid neoplasia. In our case
study, we therefore include the localization of Cyclin D1
at the messenger RNA (in situ hybridization) and protein
(immunohistochemistry) level.
Case presentation
A 63-year-old Saudi female, who was known to have
hypertension and hyperlipidaemia, complained of
fatigue, bone and muscle pain of several years of duration.
She also had a history of recurrent nephrolithiasis. Her
symptoms aggravated recently with several attacks of
abdominal pain, nausea and vomiting. Neck examination
revealed a left lower cervical mass, consistent with thyroid
enlargement. Ultrasonography showed an enlarged left
lobe with multiple hypoechoid and isoechoid nodules.
One of them in the anterior-inferior aspect of the left lobe
displayed a rim of calcification. Thyroid function test were
within the normal range. Parathyroid imaging scan using
99m Tc-SestaMIBI-99c-Pertechnetate was consistent with
scintigraphic features of a parathyroid adenoma (Figure
1) in the region of left lower parathyroid gland. X-ray
showed a "salt and pepper" skull and diffuse osteopenia.
The fine needle aspiration (FNA) of the cervical mass was
performed to evaluate left thyroid pathology and showed
findings consistent with parathyroid neoplasm.
The patient was admitted and loaded with intravenous
saline followed by Furosemide (10 mg) the day before
surgery, which was able to bring the serum calcium to
3.59 on the day of surgery. The patient was taken to the
operating room where a video-assisted exploration of the
left neck was attempted. The surgeon's plan was to remove
the diseased parathyroid gland and to take out the
enlarged left hemithyroid, followed by frozen section
evaluation. Total thyroidectomy is only performed in our
clinic, if frozen sections yield evidence of a differentiated
thyroid carcinoma greater than one centimeter in diame-
ter. A normal lower left parathyroid gland was identified
in the left thymic horn and preserved. The left thyroid
lobe appeared enlarged and showed only one distinct
nodule near the upper pole, which was sent for frozen sec-
tion diagnosis. It turned out to be benign thyroid tissue.
The surgeon decided then to remove the left thyroid lobe
after full neck exploration including the superior medi-
astinum that revealed four benign central neck lymph
nodes.
The pathology report described a thyroid lobe with a large
tumor mass, measuring 6 × 5 cm and weighing 8.5 g. It
appeared poorly circumscribed and of hard consistence.
The mass showed a gray-whitish color with occasional
foci of necrosis. A firm fibrous capsule surrounded it. The
tumor occupied nearly the whole thyroid gland. Histology
showed that thick, sharply outlined bands of collagenous
tissue extended from the thickened capsule into the inte-
rior and completely divided the tumor into irregular lob-
ules. The tumor cells were arranged in diffuse masses,
solid sheets or closely packed nests of cells (Figure 2). The
tumor cells mostly showed round to ovoid, markedly
enlarged nuclei with prominent nucleoli and clearly
demarcated cytoplasm. Parts of the tumor consisted of
Parathyroid carcinoma occupying nearly the whole thyroid gland (Th) Figure 1
Parathyroid carcinoma occupying nearly the whole thyroid gland (Th). Thick sharply outlined bands of acellular collagenous tis-
sue completely divide the tumor into irregular lobules. The tumor cells are arranged in diffuse masses, solid sheets, closely 
packed nests or compact trabeculae (H&E). Bar: 250 μm.Diagnostic Pathology 2008, 3:46 http://www.diagnosticpathology.org/content/3/1/46
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cells with abundant, clear to eosinophillic cytoplasm,
nuclear pleomorphism, marked cellular atypia. Occasion-
ally macronucleoli and multinucleated giant cells were
found. Mitoses were difficult to detect (2 per 10 high
power fields). Scattered foci of necrosis and hemorrhage
occurred at the periphery of the tumor. Capsular and vas-
cular invasion with tumor cells was observed. Extra-capsu-
lar infiltration into the adjacent soft tissue and skeletal
structures was also found. The tumor obviously had
destroyed most of thyroid gland, leaving only a thin rim
of normal thyroid tissue at the periphery (Figure 2). None
of the four lymph nodes draining the suspicious left par-
athyroid gland showed tumor involvement.
Clarification of the molecular pathogenesis of parathy-
roid carcinoma can aid in diagnostically difficult cases
and may provide important clues for a more effective ther-
apy. Therefore, tumor samples (one with a histologically
verified parathyroid carcinoma and four additional speci-
men with histologically diagnosed parathyroid adenoma)
were studied using in situ hybridization and immunocy-
tochemistry with monoclonal antibodies. Formalin-fixed
(3.7%), paraffin-embedded samples were used to localize
mRNA transcripts for Cyclin D1. In situ hybridisation was
performed as previously described. The sequences of the
oligonucleotides were designed using the program
Primer3 http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi. The sequences of the antisense oligo-
nucleotides for Cyclin D1 was as follows: 5'gtt cct cgc aga
cct cca gca tcc ag3' Acc.Nr: NM_053056 (NCBI). Immuno-
histochemical staining was performed with monoclonal
anti-Cyclin D1 anti-body (Novocastra/Vector, Burlin-
game, CA, USA), at dilution of 1:100, using a standard avi-
din/biotin complex (ABC) method. Breast cancer cases
known to express Cyclin D1 served as positive control for
Cyclin D1. For negative control, non-immune serum was
substituted for primary antibody.
Using in situ hybridization we found a weak to distinct
signal for CD1 in the cytoplasm of glandular cells of the
parathyroid adenoma tissue (Figure 3). No staining was
seen in the fibrous stroma that occasional formed broad
bands in the neoplasm. Parathyroid carcinoma cells
showed a variable staining with the probe used: Cells
strongly positive from CD1 mRNA varied with only
weakly stained tumor cells. (Figure 4). The giant cells
always displayed a strong signal for CD1-mRNA. All 4
adenoma samples showed a weak to distinct immunos-
taining for the CD1 protein in their cytoplasm. In about
20% of the cells, also a nuclear staining occurred. The cor-
responding stroma in the adenomas showed no immuno-
reactivity for CD1. Also with immunohistochemistry,
parathyroid carcinoma cells showed a variable staining for
CD1 and carcinoma cells strongly positive from CD1
mRNA varied with only weakly stained tumor cells (Figure
5). Therefore, the most distinct feature distinguishing par-
athyroid adenoma from parathyroid carcinoma cells is the
occurrence of strongly CD1 positive cells in the carcinoma
areas.
At the postoperative patient visit, a week after surgery, the
serum calcium has dropped to 2.38 mg/dl (2.10–2.55),
the parathormone (PTH) level has returned to normal val-
ues, however alkaline phosphatase remained high (628
U/L). CT scan of the brain and lungs revealed no evidence
99m Tc SestaMIBI "A" nodular left lobe with sizeable lower  pole Figure 2
99m Tc SestaMIBI "A" nodular left lobe with sizeable lower 
pole. "B" prominent focal area in the lower pole of the left 
lobe of the thyroid. "C" substraction image show the promi-
nent hot area (arrow) to be located in the hot area "A".
In situ hybridization of Cyclin D1 in a parathyroid adenoma Figure 3
In situ hybridization of Cyclin D1 in a parathyroid adenoma. 
Cytoplasm and nuclei contain a slight to distinct signal for 
CD1 mRNA. Bar: 100 μm.Diagnostic Pathology 2008, 3:46 http://www.diagnosticpathology.org/content/3/1/46
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of metastasis. At follow-up three months after surgery, the
patient appeared disease free with normal levels of PTH
and calcaemia and improvement of the bone disease
symptoms. The patient is now, two years from surgery,
disease free and her serum calcium and parathormone
level remained in the normal range.
Conclusion
Parathyroid carcinoma is a rare malignancy with an inci-
dence of less than 1% in all patients surgically treated for
primary hypoparathyroidism [8-12]. A higher rate of
about 5% has only reported in few countries, like Japan
and Italy [13]. Most reports indicate equal gender distri-
bution and a mean age of 48 years, a decade earlier than
adenoma. The clinical manifestations of hyperparathy-
roidism in parathyroid carcinoma are usually more severe
than in patients with parathyroid adenoma with markedly
elevated serum calcium levels (and resulting symptoms
like muscle weakness, fatigue, depression, nausea, polyu-
ria) and parathormone (PTH) levels [14,15]. In our case
PTH level was more phosphatase was also significantly
higher.
The diagnosis of malignancy was made post operatively.
The fine needle aspiration performed intra operatively
was done to evaluate the left thyroid lobe lesion rather
and revealed normal thyroid tissue. None of the preoper-
ative studies raised suspicion of the presence of parathy-
roid malignancy and the probability to find a parathyroid
carcinoma in patients with palpable parathyroid glands,
marked elevation of serum calcium and parathormone
[14,15] is less than 5%. Due to the intrathyroidal location
[16-18], there was no strong indication of malignancy in
this case at the beginning. Severe symptoms of renal dis-
An interesting pattern of CD1-mRNA distribution was seen in the carcinomatous areas, where strongly staining tumor cells  varied with nearly CD1-negative ones Figure 4
An interesting pattern of CD1-mRNA distribution was seen in the carcinomatous areas, where strongly staining tumor cells 
varied with nearly CD1-negative ones. The inset shows giant cells distinctly positive for CD1-mRNA. Bar: 100 μm.Diagnostic Pathology 2008, 3:46 http://www.diagnosticpathology.org/content/3/1/46
Page 5 of 6
(page number not for citation purposes)
ease (impaired renal function, nephrolithiasis, nephrocal-
cinosis) are also requent in patients with benign
parathyroid tumors. Bone pain, "salt and pepper " skull
and diffuse osteopenia were the bone symptoms present
in our patient. The combination of both renal and bone
symptomes at presentation and the presence of a palpable
neck mass raised the suspicion of malignancy [16].
The suspicion that the removed tumor tissue may be a par-
athyroid carcinoma could be confirmed by histology. In
our case, invasion of tumor cells was found in the vessels
and neighboring muscle tissue, which has been seen also
in other studies [3,10]. Cellular atypia and variation, also
seen in the tumor samples of our case, are not particular
useful criteria to diagnose a parathyroid carcinoma, as no
specific morphologic criteria exist. In 1993, Bondeson et
al. [9] reported that parathyroid carcinoma may have such
bland cytologic appearance that nothing but the invasive-
ness of the tumor can differentiate them from a benign
lesion, although fibrosis, necrosis, nuclear atypia (pleo-
morphism macronucleoli, large nuclei) and mitotic fig-
ures are significantly more frequent in carcinoma.
Capsular invasion is present in 60% of the parathyroid
carcinomas. They affect the surrounding skeletal muscle,
thyroid gland [17,18] or other tissues. Vascular invasion is
characterized by carcinoma cells present within vessels of
the fibrous tumor capsule. This is not a very common
finding in carcinoma, but was present in our case and can
be interpretated as clear sign of malignancy [10]. Solid
growth of the parathyroid carcinoma with tumor cells
arranged in diffuse masses, small nests or trabeculae are
typically found [10]. All these histological features were
found in our case. In other cases of parathyroid carcino-
mas follicular or spindle cell patterns or, rarely, papillary
growth has been reported [1,10].
A change in the expression of CD1 mRNA has been found
during the progression from benign to malignant parath-
yroid tumor cells CD1 oncoprotein is overexpressed fre-
quently in parathyroid carcinoma [5-7]. It was proposed
that s could be used as some additional diagnostic criteria
[7]. In our case, the only clearly seen difference in the
expression of CD1 in benign versus malign parathyroid
tissue was the occurrence of strongly CD1 positive giant
cells within the carcinoma. Using immunocytochemistry,
these cells are easily found and could support the patho-
histological diagnosis.
In summary, parathyroid carcinoma is a rare malignancy.
Signs and symptoms of hypocalcaemia, hyperparathyroid
bone disease and features of renal involvement along with
a palpable neck mass are strong predictors of parathyroid
malignancy. It is usually difficult to recognize the tumor
preoperatively and it is not conclusively identified intra-
operatively. Pathologic histology including in situ hybrid-
ization and immunohistochemistry of cyclin D1 helps to
characterize the lesion and confirms its nature.
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